Last reviewed · How we verify
Sumatriptan-naproxen combination — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Sumatriptan-naproxen combination (Sumatriptan-naproxen combination) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Sumatriptan-naproxen combination TARGET | Sumatriptan-naproxen combination | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Sumatriptan-naproxen combination CI watch — RSS
- Sumatriptan-naproxen combination CI watch — Atom
- Sumatriptan-naproxen combination CI watch — JSON
- Sumatriptan-naproxen combination alone — RSS
Cite this brief
Drug Landscape (2026). Sumatriptan-naproxen combination — Competitive Intelligence Brief. https://druglandscape.com/ci/sumatriptan-naproxen-combination. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab